Research programme: inflammation therapy - Immusol/Vertex
Latest Information Update: 28 Sep 2006
At a glance
- Originator Immusol; Vertex Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 28 Sep 2006 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 16 Apr 2003 PanVera LLC has been acquired by Invitrogen
- 07 May 2002 Preclinical trials in Inflammation in USA (unspecified route)